376 related articles for article (PubMed ID: 19018090)
41. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
42. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
[TBL] [Abstract][Full Text] [Related]
43. Autologous stem-cell transplantation in patients with HIV-related lymphoma.
Balsalobre P; Díez-Martín JL; Re A; Michieli M; Ribera JM; Canals C; Rosselet A; Conde E; Varela R; Cwynarski K; Gabriel I; Genet P; Guillerm G; Allione B; Ferrant A; Biron P; Espigado I; Serrano D; Sureda A
J Clin Oncol; 2009 May; 27(13):2192-8. PubMed ID: 19332732
[TBL] [Abstract][Full Text] [Related]
44. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
Czyz J; Hellmann A; Dziadziuszko R; Hansz J; Goździk J; Hołowiecki J; Stella-Hołowiecka B; Kachel Ł; Knopińska-Posłuszny W; Nagler A; Meder J; Walewski J; Lampka E; Sułek K; Sawicki W; Lange A; Forgacz K; Suchnicki K; Pacuszko T; Skotnicki A; Mensah P; Jurczak W; Kuliczkowski K; Wróbel T; Mazur G; Dmoszyńska A; Wach M; Robak T; Warzocha K
Bone Marrow Transplant; 2002 Jul; 30(1):29-34. PubMed ID: 12105774
[TBL] [Abstract][Full Text] [Related]
45. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
Claviez A; Sureda A; Schmitz N
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
[TBL] [Abstract][Full Text] [Related]
46. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A
Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
[TBL] [Abstract][Full Text] [Related]
47. [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease].
Minigo H; Vrhovac R; Kalac M; Jaksić B
Acta Med Croatica; 2009 Jun; 63(3):215-7. PubMed ID: 19827348
[TBL] [Abstract][Full Text] [Related]
48. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial.
Brinkman DM; de Kleer IM; ten Cate R; van Rossum MA; Bekkering WP; Fasth A; van Tol MJ; Kuis W; Wulffraat NM; Vossen JM
Arthritis Rheum; 2007 Jul; 56(7):2410-21. PubMed ID: 17599770
[TBL] [Abstract][Full Text] [Related]
49. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
50. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
51. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
Pettengell R
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153
[TBL] [Abstract][Full Text] [Related]
52. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
53. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey.
Kuittinen T; Wiklund T; Remes K; Elonen E; Lehtinen T; Kuittinen O; Leppä S; Putkonen M; Räty R; Turpeenniemi-Hujanen T; Nousiainen T; Jantunen E
Eur J Haematol; 2005 Sep; 75(3):199-205. PubMed ID: 16104875
[TBL] [Abstract][Full Text] [Related]
54. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation.
Streetly M; Kazmi M; Radia D; Hoyle C; Schey SA
Bone Marrow Transplant; 2004 Jun; 33(11):1131-5. PubMed ID: 15094743
[TBL] [Abstract][Full Text] [Related]
55. In vivo purging and relapse prevention following ASCT.
Gisselbrecht C
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S5-9. PubMed ID: 11840154
[TBL] [Abstract][Full Text] [Related]
56. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.
Sieniawski M; Staak O; Glossmann JP; Reineke T; Scheuss H; Diehl V; Engert A; Josting A
Ann Hematol; 2007 Feb; 86(2):107-15. PubMed ID: 17103169
[TBL] [Abstract][Full Text] [Related]
57. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.
Fung HC; Stiff P; Schriber J; Toor A; Smith E; Rodriguez T; Krishnan A; Molina A; Smith D; Ivers B; Kogut N; Popplewell L; Rodriguez R; Somlo G; Forman SJ; Nademanee A
Biol Blood Marrow Transplant; 2007 May; 13(5):594-600. PubMed ID: 17448919
[TBL] [Abstract][Full Text] [Related]
58. Optimal treatment for relapsing patients with Hodgkin lymphoma.
Sibon D; Brice P
Expert Rev Hematol; 2009 Jun; 2(3):285-95. PubMed ID: 21082970
[TBL] [Abstract][Full Text] [Related]
59. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
60. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Bishton MJ; Lush RJ; Byrne JL; Russell NH; Shaw BE; Haynes AP
Br J Haematol; 2007 Mar; 136(5):752-61. PubMed ID: 17313378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
